BriaCell Therapeutics Corp. (BCTXL)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BriaCell Therapeutics Corp.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 0.8100 | 0.9100 | 0.7900 | 0.8000 | 78,676 |
| Nov 16, 2026 | 0.8900 | 0.9617 | 0.7750 | 0.8200 | 10,498 |
| Nov 13, 2026 | 0.9700 | 0.9800 | 0.8707 | 0.8708 | 17,530 |
| Nov 12, 2026 | 0.8900 | 0.9500 | 0.8900 | 0.9200 | 10,901 |
| Nov 11, 2026 | 0.9700 | 0.9700 | 0.9200 | 0.9700 | 9,024 |
| Nov 10, 2026 | 1.01 | 1.02 | 0.8500 | 0.9800 | 22,071 |
| Nov 9, 2026 | 1.02 | 1.05 | 0.9900 | 0.9975 | 13,784 |
| Nov 6, 2026 | 0.8999 | 1.00 | 0.8750 | 0.9750 | 40,531 |
| Nov 5, 2026 | 0.8300 | 0.9000 | 0.7850 | 0.8100 | 39,246 |
| Nov 4, 2026 | 0.8366 | 0.8366 | 0.8130 | 0.8250 | 13,630 |
| Nov 3, 2026 | 0.8200 | 0.8400 | 0.8050 | 0.8399 | 5,651 |
| Nov 2, 2026 | 0.7000 | 0.8617 | 0.7000 | 0.7500 | 8,800 |
| Oct 30, 2026 | 0.8300 | 0.9000 | 0.7200 | 0.8105 | 22,409 |
| Oct 29, 2026 | 0.8750 | 0.9000 | 0.8300 | 0.9000 | 3,403 |
| Oct 28, 2026 | 0.8800 | 0.8927 | 0.8400 | 0.8400 | 5,482 |
| Oct 27, 2026 | 0.7900 | 0.8700 | 0.7900 | 0.8500 | 3,660 |
| Oct 26, 2026 | 0.8800 | 0.8800 | 0.7002 | 0.8700 | 5,663 |
| Oct 23, 2026 | 0.8990 | 0.9000 | 0.8850 | 0.8899 | 11,577 |
| Oct 22, 2026 | 0.9099 | 0.9100 | 0.8850 | 0.9025 | 8,947 |
| Oct 21, 2026 | 0.9200 | 0.9399 | 0.9000 | 0.9300 | 17,170 |
| Name | Shares | % | Source |
|---|---|---|---|
CITADEL ADVISORS LLC BCTXL | 850.9K | -- | 13F |
ARMISTICE CAPITAL, LLC BCTXL | 536.6K | -- | 13F |
Cable Car Capital, LP BCTXL | 321.9K | -- | 13F |
Empery Asset Management, LP BCTXL | 300.0K | -- | 13F |
MYDA Advisors LLC BCTXL | 195.0K | -- | 13F |
HEIGHTS CAPITAL MANAGEMENT, INC BCTXL | 186.6K | -- | 13F |
Warberg Asset Management LLC BCTXL | 181.6K | -- | 13F |
SABBY MANAGEMENT, LLC BCTXL | 136.4K | -- | 13F |
Clear Street Group Inc. BCTXL | 104.2K | -- | 13F |
IRIDIAN ASSET MANAGEMENT LLC/CT BCTXL | 65.0K | -- | 13F |
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer.
The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay.
The company's main offices are situated in West Vancouver, Canada.
based on 8.73M shares outstanding
30d Avg
16.95K
60d Avg
17.30K
90d Avg
16.66K
BriaCell Therapeutics Corp. (NASDAQ: BCTXL) traded at $0.8000 on Nov 17, 2026, down 2.44% from the previous close of $0.8200. 52-week range: $0.7900 to $1.23. The company is in the Healthcare sector (Biotechnology).